Covestor LTD United Therapeutics Corp Transaction History

Covestor LTD

$160 Million
Q3 2024

A detailed history of Covestor LTD transactions in United Therapeutics Corp stock. As of the latest transaction made, Covestor LTD holds 289 shares of UTHR stock, worth $104,291. This represents 0.06% of its overall portfolio holdings.

Number of Shares

289

Previous 465 37.85%

Holding current value

$104,291

Previous $148,000 30.41%

% of portfolio

0.06%

Previous 0.1%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	SELL	$311.04 - $363.55 $54,743 - $63,984	-176 Reduced 37.85%	289 $103,000
Q2 2024 Aug 09, 2024	SELL	$228.26 - $319.04 $10,043 - $14,037	-44 Reduced 8.64%	465 $148,000
Q1 2024 May 10, 2024	BUY	$210.76 - $249.51 $48,685 - $57,636	231 Added 83.09%	509 $117,000
Q4 2023 Feb 09, 2024	SELL	$214.88 - $256.94 $114,745 - $137,205	-534 Reduced 65.76%	278 $61,000
Q3 2023 Nov 13, 2023	SELL	$211.82 - $248.24 $76,678 - $89,862	-362 Reduced 30.83%	812 $183,000
Q2 2023 Aug 11, 2023	BUY	$205.19 - $232.99 $54,785 - $62,208	267 Added 29.44%	1,174 $259,000
Q1 2023 May 15, 2023	BUY	$212.99 - $276.17 $3,194 - $4,142	15 Added 1.68%	907 $203,000
Q4 2022 Feb 13, 2023	SELL	$205.95 - $280.43 $3,501 - $4,767	-17 Reduced 1.87%	892 $248,000
Q3 2022 Nov 14, 2022	SELL	$203.3 - $244.17 $1,626 - $1,953	-8 Reduced 0.87%	909 $190,000
Q2 2022 Aug 10, 2022	BUY	$174.81 - $241.14 $6,992 - $9,645	40 Added 4.56%	917 $216,000
Q1 2022 May 13, 2022	BUY	$166.16 - $213.96 $95,043 - $122,385	572 Added 187.54%	877 $157,000
Q4 2021 Feb 10, 2022	BUY	$184.32 - $216.08 $56,217 - $65,904	305 New	305 $66,000

Others Institutions Holding UTHR

# of Institutions

671

Shares Held

42.3M

Call Options Held

194K

Put Options Held

295K

View Full List

About UNITED THERAPEUTICS Corp

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.4B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

More about UTHR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Covestor LTD, based on Form 13F filings with the SEC.

News

Stay updated on Covestor LTD with notifications on news.

Account